Clinical Trial Update: BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bevacizumab for efficacy and safety in reducing severe bleeding in hereditary hemorrhagic telangiectasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic | Phase 3 | Status: COMPLETED